MedAssets pullback brings attractive entry point, says Lazard Capital Lazard Capital says the recent pullback in shares of MedAssets provides an attractive entry point as it does not see any change in the company's fundamentals. The firm reiterates a Buy rating on the name with a $22 price target.
News For MDAS From The Last 14 Days
Check below for free stories on MDAS the last two weeks.
MedAssets upgraded to Outperform from Market Perform at Leerink Leerink upgraded MedAssets to Outperform citing the pullback in shares since the Q2 results, the potential for improving volumes in Q3 and the company's total portfolio approach. The firm has a $26 price target for shares.
MedAssets pullback a buying opportunity, says Jefferies Jefferies believes MedAssets' core business is back on track following yesterday's analyst day and it recommends buying the stock on the recent pullback. The firm has a Buy rating on the name with a $30 price target.